Fritextsökning
Innehållstyper
-
List: The companies behind 38 new pharmaceutical substances in the EU
In 2025, the European Medicines Agency (EMA) recommended 104 medicines for approval. Of these, 38 contained a new active substance that had never before been au...
-
From Image to Results
3D multiplexing spatial omics workflows in neuroscience.
-
New findings on the diseases that crushed Napoleon’s army
As if cold, starvation, and typhus weren’t enough. New research reveals that Napoleon’s defeated army also suffered from paratyphoid fever and relapsing fever d...
-
Scientist – Cell Biology and Immunology
Affibody is looking to recruit a Scientist in cell biology and immunology for the In Vitro Pharmacology (IVP) group. The location is in Affibody’s premises at K...
-
How the Nobel discovery is used in drug development
Regulatory T cells keep the immune system in check, a discovery now awarded the 2025 Nobel Prize in Physiology or Medicine. Qiang Pan Hammarström explains how t...
-
PharmaRelations appoints new Chief Digital Officer and Executive VP Denmark
Press Release
-
Collaboration across the Øresund – Camurus enters Danish licensing agreement
Lund‑based Camurus has entered into a collaboration and licensing agreement with Danish company Gubra, which specializes in peptide‑based drug development.
-
Acne medication may be the solution when hair starts falling out
A treatment originally developed for acne has shown remarkable Phase III results in a completely different area: male-pattern hair loss.
-
Obesity dominates as future blockbusters are identified
Two drug candidates targeting obesity and diabetes stand out sharply in Clarivate’s newly selected “starting eleven” of potential future blockbusters worth watching.
-
Gothenburg-based Anyo Labs gains ground in the AI race
In a fifty-square-metre space in Gothenburg sits a company aiming to secure its place on one of the world's hottest technological stages: AI-driven drug develop...
-
Gene therapy restored hearing in children with congenital deafness
Eleven out of twelve children with congenital deafness showed improvements in a study testing Regeneron’s gene therapy for hereditary hearing loss. The U.S. com...
-
The Beauty of Clinical Microscopy of Urine Sediment
Read about concrete observations using phase contrast and polarized light.
-
“Access to capital increases when there’s an exit”
It remains a tough environment for biotech companies seeking financing – but there is good reason to hope for improvement ahead. That’s the view of Okee William...
-
Experience innovations of the future
ZEISS QUALITY INNOVATIONS WORLDWIDE event in Oberkochen, Germany, January 20-21, 2026.
-
Shaping the Future of Metrology – Live in Your Region
Insights into our event series.
-
ZEISS EVO as the Key to Wire Technology in Modern Medicine
High-performance wires for stents.
-
Unlocking Predictive Insights for Drug Discovery and Development
3D tissue models webinar series.
-
Investor Network Backs Early-Stage Nordic Innovation
Life Science Invest is expanding into the Nordic region and has secured SEK 31 million to invest in early-stage research companies. The capital will be invested...
-
FDA’s new CSA guidance: transforming software validation for production and quality systems
FDA’s final guidance on Computer Software Assurance (CSA) for Production and Quality System Software marks a significant modernization of software validation practices.
-
Sneak Peek of ZEISS Metrology Expert Tips Season 2
The second season of the video series starts in January 2026, but you can discover more about the highlights of Season 2 now.
-
Fourteen US-based top researchers recruited to Sweden
Last year, the government launched an initiative to attract leading researchers to Sweden, with a particular focus on academics based in the United States. As t...
-
“There’s no magic wand” – The urgent need for new treatments
One in ten women with recurrent yeast infections develops a stubborn, hard-to-treat condition for which no effective therapies currently exist. At Danderyd Hosp...
-
Phase III win for Hansa Biopharma: “We Are Thrilled”
Swedish biotech Hansa Biopharma’s transplant drug imlifidase has met the primary efficacy endpoint in a registration-enabling Phase III study in the United States.
-
Webinar: Fast and Gentle Imaging of Developing Human Spinal Cord Organoids with ZEISS Lattice Lights
Imaging of complex in-vitro models.
BREAKING